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Women with von Willebrand disease (VWD) are at
increased risk of pregnancy-related bleeding, including
postpartum haemorrhage (PPH) compared to women
without VWD [1–4]. In healthy women without
VWD, levels of VWF and FVIII increase two- to four-
fold during pregnancy, peaking within 24 h postpar-
tum and decrease to baseline levels by 1 month
postpartum [5–7]. Type 1 VWD, accounting for
approximately 80% of patients with VWD, is charac-
terized by a parallel deficiency of von Willebrand fac-
tor antigen and activity. In cross-sectional analyses of
values in women with type 1 VWD, levels of VWF
and FVIII also increase during pregnancy, usually to
within the normal range [8,9]. Prospective analyses of
levels in women with VWD in the peripartum period
show that levels peak early after delivery and return
to baseline by approximately 3 weeks postpartum
[10,11]. Longitudinal data evaluating changes earlier
in pregnancy are lacking.
The goal of this study was to model changes in
VWF levels during and up to 6 weeks postpartum in
women with type 1 VWD and correlate findings with
blood loss. A secondary goal was to identify potential
predictors of bleeding with delivery in women with
type 1 VWD.
Women with type 1 VWD, defined as at least one
value of VWF antigen (VWF:Ag) or VWF activity
(VWF:Act) <50%, VWF Act/Ag >0.7, and compatible
history of mucosal bleeding prepregnancy, age 18 or
older, were recruited prior to 36 weeks gestation. The
study was terminated early due to low enrolment.
Women with a twin gestation, additional bleeding dis-
order, or use of anticoagulant or antiplatelet therapy
were excluded. All subjects gave written informed
consent before enrolment, and the study was IRB
approved at each participating institution.
Baseline data included demographics, bleeding
symptoms, a modified bleeding score[12] and prior
history of PPH, if any. Data collected at time of
labour, 24–48 h, 48 h–1 week, 1–2 and 6 weeks post-
partum included method of delivery, complications,
estimated blood loss (EBL), need for haemostatics or
blood products and bleeding or VWD diagnosis in the
infant. FVIII, VWF:Ag and VWF:Act were obtained
monthly after enrolment, at presentation in labour
and postpartum (12, 24 and 48 h and 1, 2 and
6 weeks). Cord blood was obtained at the time of
delivery. Platelet-poor plasma was prepared locally
from all samples (3.2% Na citrate anticoagulation)
within 3 h of collection, frozen at 80°C and assayed
centrally [one-stage factor VIII activity (MDA 180,
Platelin L activator, BioMerieux, Durham, NC),
VWF:Ag and VWF:Act by ELISA (American Biochem-
ical and Pharmaceuticals Ltd, Epsom, Surrey, UK)].
Univariate analyses were carried out with the stu-
dent t-test and chi-squared test to compare the differ-
ence in continuous and categorical variables,
respectively. Change in VWF:Ag levels during gesta-
tion and postpartum was modelled using longitudinal
regression analysis. A mixed-effects exponential
growth model was used in the gestational period and
an exponential decay model was used in the postpar-
tum period. All analyses were performed using either
R version 2.12 (R Foundation for Statistical comput-
ing, Vienna, Austria) or Stata 12 (StataCorp, College
Station, TX).
Twelve women were recruited from four institu-
tions, with a median age of 31.3 years (range: 19–43).
All were Caucasian of non-Hispanic ethnicity. One
patient dropped out at 21 weeks’ gestation. Most
were blood type O (67%), and 5 of 12 (42%) were
nulliparas. Three subjects reported prior PPH (27%).
The mean baseline bleeding score was 8 [standard
deviation (SD) 7]. Mean weeks’ gestation at delivery
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was 39 (SD: 1), with two caesarean deliveries (18%).
Seven women (64%) used epidural anaesthesia, and
one woman each used spinal, general, local or no
anaesthesia. Seven women (64%) suffered some degree
of genital tear. Mean EBL was 528 mL (SD: 354).
One woman experienced immediate PPH, ascribed to
uterine atony and requiring a 2-unit RBC transfusion,
and one woman had secondary PPH at 48 h and self-
treated at home with intranasal desmopressin. Three
women were treated with VWF concentrate peri- and
postpartum, one for a history of PPH, one for low
VWF levels and the third for unclear reasons. None of
the women required readmission, ICU stay or invasive
procedures to stop bleeding.
Mean VWF:Ag, VWF:Act and FVIII levels at base-
line, at presentation in labour and 6 weeks postpar-
tum are shown in Table 1. VWF:Ag and VWF:Act
levels correlated well throughout for each woman (r
0.91, P < 0.01). The rate of change of VWF levels
was heterogeneous and varied individually, with dif-
ferences between VWF:Ag value at baseline vs. labour
ranging from 43 to 164% and labour vs. 6 weeks
postpartum ranging from 21 to 128% (Fig. 1).
During the gestational period, a mixed-effects expo-
nential growth model best fit the rise in VWF:Ag level
at labour relative to prepregnancy, VWF:Ag = exp
(0.028 9 gestational age in weeks), SD: 0.007. In this
model, VWF:Ag is predicted to double from 19 weeks
upwards and some individuals would not double prior
to entering labour (RLR
2 = 0.58). Postpartum, an
exponential decay model was fit to the decline in
VWF:Ag from labour to 2 weeks PP, VWF:Ag = exp
(0.40 9 gestational age in weeks), SD: 0.19
(R2=0.79). This model predicted VWF:Ag levels
should return to baseline by mean 3.8 weeks (SD: 2.6)
postpartum. Poor fit of the exponential decay model
in the 2- to 6-week postpartum time period suggests
that after 2 weeks postpartum, decay in VWF:Ag is
no longer exponential. Modelling results were similar
if VWF:Act was used. In the study by James and col-
leagues, which elucidated the changes in VWF levels
postpartum in more detail, VWF levels decayed
rapidly and approached baseline at 1 week and then
more slowly reached baseline levels at 3 weeks [11],
consistent with our findings.
Using cross-sectional analyses, Cadroy and col-
leagues modelled changes in VWF:Ag levels during
normal pregnancy over 5–39 weeks’ gestation [9].
They also used an exponential growth model to fit
their independent VWF:Ag measurements, which was
expressed as VWF:Ag = 6.39*exp[0.017 9 Gest.Age
(weeks)]. Cadroy’s estimates of VWF:Ag changes in
non-VWD women (0.017) were at the low end of
growth rate estimates from our model of type 1 VWD
women (0.016-0.039), suggesting that VWF:Ag levels
change more dynamically during pregnancy in women
with type 1 VWD than in normal women.
Increased EBL was associated with caesarean deliv-
ery (r, P-value: 0.76, 0.02) and manual placenta deliv-
ery (0.76, 0.02). Increased haemoglobin loss from
36 weeks’ gestation to 24 h postpartum correlated
with episiotomy (0.75, 0.03) and degree of tear (0.99,
0.02). Most tears were minor [mean degree 2 (range
1–3)]. No significant correlation was found with VWF
levels at labour or bleeding score. The woman who
bled during delivery had the highest peak VWF levels
in the study (VWF:Ag 215% and VWF:Act 183% at
labour presentation) and uterine atony, the most com-
mon cause of primary PPH.
Haemostatic outcomes and VWF levels were
recorded in the neonates born to the study subjects.
All were within adult normal ranges and did not cor-
relate significantly with maternal levels at labour or
baseline (Table 1). Based on the presumed autosomal
Table 1. VWD laboratory parameters* over time.
n % VWF:Ag (SD) % VWF:Act (SD) % FVIII (SD)
Baseline 11 41.1 (7.1) 34.4 (8.4) 76.4 (70.8)
Labour 11 136.4 (50.8) 128.9 (47.8) 134.2 (42.7)
6 weeks PP 10 57.8 (22.8) 52.1 (25.4) 80.9 (32.2)
Infant cord blood 9 97.9 (35.8) 96.2 (34.8) 67.7 (22.6)
*Values shown are mean [standard deviation (SD)].
Fig. 1. von Willebrand factor antigen (VWF Ag)
levels prior to and following labour. Women with
a VWF:Ag <50% prior to pregnancy had VWF:Ag
levels measure at time points prior to, at presenta-
tion in labour and postpartum (a). Values drawn
during the first 2.5 weeks postpartum are shown
in (b).
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dominant inheritance pattern of type 1 VWD, there is
a 50% chance of having an affected child. In general,
it is assumed that neonates with type 1 VWD have
elevated levels at birth secondary to the stress of birth
and should not experience haemorrhage with haemo-
static challenges. In our study, no infants had bleeding
symptoms and were diagnosed with VWD or bled
with procedures (0 3; one circumcision, two blood
draws) in the first 6 weeks of life. We did not have
IRB approval to follow the infants further.
We did not perform VWF mutation analysis in our
patients. If performed in a larger number of women
with VWD, such analyses might help explain the
observed heterogeneity in responses. Type 1 VWD
results from mutations that affect VWF synthesis, pro-
cessing and/or secretion [14,15]. It would follow that
some defects may suppress or prevent expression of
pregnancy-related increases.
The major limitation of our study is the small num-
ber of patients enrolled. Compounding this is the fact
that type 1 VWD is a heterogeneous disease with a
wide variety of genotypes and phenotypes. Our defini-
tion of type 1 VWD was liberal with a baseline VWF:
Ag or Act <50%, and inconsistent with NHLBI rec-
ommendations of values <30% [13]. Nevertheless, we
also required a history of excessive mucosal bleeding,
substantiated by the women’s elevated bleeding scores.
Despite these limitations, the strengths of our study
include its prospective nature and close follow-up,
with chart-verified obstetric data and lack of depen-
dence on patient recall.
In conclusion, women with type 1 VWD have highly
individual and heterogeneous rates of rise and decline
of VWF levels during gestation and postpartum. An
exponential growth and decay model was fit to the
VWF:Ag peripartum levels up to 2 weeks postpartum.
In our study, VWF levels were not correlated signifi-
cantly with blood loss, although, of note, all subjects’
VWF levels were >50% at the time of delivery. The
children born to study subjects had normal FVIII and
VWF levels and did not have bleeding complications.
While this study is small and the population is
homogenous, it confirms the variable rise and fall in
VWF levels and supports the practice of assessing fac-
tor levels in women with VWD during pregnancy.
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